HJMC
MRNA icon

Hellman Jordan Management Company’s Moderna MRNA Stock Holding History

Hellman Jordan Management Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.09M Buy
6,073
+516
+9% +$84.4K 1.85% 22
2022
Q3 		$657K Buy
+5,557
New +$843K 1.14% 29
2021
Q4 		– Sell
-1,544
Closed -$594K – 70
2021
Q3 		$594K Sell
1,544
-1,156
-43% -$426K 0.84% 46
2021
Q2 		$634K Sell
2,700
-71
-3% -$12.7K 1.13% 37
2021
Q1 		$363K Buy
+2,771
New +$402K 0.53% 54
2020
Q4 		– Sell
-51,632
Closed -$3.65M – 25
2020
Q3 		$3.65M Sell
51,632
-26,600
-34% -$1.85M 6.95% 7
2020
Q2 		$5.02M Sell
78,232
-23,184
-23% -$1.27M 8.12% 5
2020
Q1 		$3.04M Sell
101,416
-65,344
-39% -$1.5M 7.19% 5
2019
Q4 		$3.26M Buy
166,760
+1,531
+0.9% +$27.2K 3.66% 8
2019
Q3 		$2.63M Buy
165,229
+3,025
+2% +$44.7K 2.09% 13
2019
Q2 		$2.38M Buy
162,204
+22,000
+16% +$473K 3.24% 9
2019
Q1 		$2.85M Buy
+140,204
New +$2.6M 1.99% 14

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hellman Jordan Management Company's MRNA Position: Q4 2022 in Review

Hellman Jordan Management Company increased its Moderna (MRNA) stake by 9.3% in Q4 2022, buying an estimated $84.4K and bringing the position to 6,073 shares worth $1.09M. The position accounts for 1.85% of the portfolio, ranked #22.

Hellman Jordan Management Company first reported a position in MRNA in Q1 2019 and has held it in 12 quarters since. The position peaked at $5.02M in Q2 2020. 1,072 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Hellman Jordan Management Company held 6,073 shares of Moderna worth $1.09M as of Q4 2022.
  • Hellman Jordan Management Company bought 516 Moderna shares in Q4 2022, an estimated $84.4K.
  • Moderna made up 1.85% of Hellman Jordan Management Company's portfolio in Q4 2022, its #22 holding.
  • Hellman Jordan Management Company first reported a position in Moderna in Q1 2019 and has held it in 12 quarters since.
  • Hellman Jordan Management Company's Moderna position peaked at $5.02M in Q2 2020.
  • 1,072 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Hellman Jordan Management Company's 13F filing for Q4 2022, filed 20 Jan 2023.